Oxford Biomedica Company News

Epic Code:
Sub Sector:
Market Cap:

Pharmaceuticals & Biotechnology
UK Main Market
60.6936153375 GBPm

Data as of 10:00 23/09/2009. Check director details and other company announcments at Oxford Biomedica Website .

RNS News for Oxford Biomedica

Regulatory News Service : RNS provides a service that enables local or international listed companies to meet company news reporting obligations in UK, Europe and US - international filings use different processes: Provides investors & professionals equal access to new company information as it is released. For further details of RNS news see London Stock Exchange website.

Latest Oxford Biomedica News

DIRECTOR DEALINGS: Oxford BioMedica Chief Business Officer Lifts Stake
London South East (registration) (blog) - Jul 17, 2017
LONDON (Alliance News) - Oxford BioMedica PLC said Chief Business Officer Peter Nolan bought 249,687 shares at a price of 8.01 pence per share Monday.
How Analysts Rated Oxford BioMedica plc (LON:OXB) Last Week? - WeeklyHub
Insider Buying: Oxford BioMedica plc (OXB) Insider Acquires 49033 Shares of Stock - Sports Perspectives

07/17/2017 01:14 PM

Oxford Biomedica extends contract with Swiss pharma giant Novartis
Proactive Investors UK - Jul 6, 2017
Oxford Biomedica (LON:OXB) saw its shares edge higher today on news it has extended its partnership with pharmaceutical giant Novartis, signing a new contract for the commercial and clinical supply of its LentiVector gene delivery technology.
Oxford BioMedica Signs USD100 Million Supply Agreement With Novartis - London South East (registration) (blog)
Oxford Biomedica Signs 3-Year Commercial, Clinical Supply Agreement with Novartis - Fox Business

07/06/2017 08:48 AM

Oxford BioMedica Agrees USD55 Million Debt Facility With Oaktree (ALLISS)
London South East (registration) (blog) - Jun 30, 2017
LONDON (Alliance News) - Oxford BioMedica PLC on Friday said it has agreed a new USD55.0 million debt facility with Oaktree Capital Management - Strategic Credit Strategy.

06/30/2017 01:00 PM

Oxford BioMedica Notes Novartis' Positive Trial Results For CTL019
London South East (registration) (blog) - Jun 14, 2017
LONDON (Alliance News) - Oxford BioMedica PLC on Wednesday noted positive results from Swiss drug giant Novartis in its phase II study of its CTL019 product for adult patients with relapsed and refractory diffuse large B-cell lymphoma.

06/14/2017 03:15 PM

Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review ...
Nasdaq - Jun 7, 2017
Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review ...

06/07/2017 02:18 PM

Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica
Financial Times - Mar 24, 2017
Shares in Bellway are trading at eight times forward earnings, below the sector average, and the company is cheaper on a price-to-net-tangibles measure too.

03/24/2017 06:02 PM